238 related articles for article (PubMed ID: 37808345)
1. Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway.
Zhang N; Liu T; Wang J; Xiao Y; Zhang Y; Dai J; Ma Z; Ma D
Drug Des Devel Ther; 2023; 17():3047-3060. PubMed ID: 37808345
[TBL] [Abstract][Full Text] [Related]
2. Si-Ni-San inhibits hepatic Fasn expression and lipid accumulation in MAFLD mice through AMPK/p300/SREBP-1c axis.
Lan T; Geng XJ; Zhang SJ; Zeng XX; Ying JJ; Xu Y; Liu SY; Li P; Tong YH; Wang W; Mao ZJ; Wang SW
Phytomedicine; 2024 Jan; 123():155209. PubMed ID: 37984123
[TBL] [Abstract][Full Text] [Related]
3. Si-Ni-San reduces lipid droplet deposition associated with decreased YAP1 in metabolic dysfunction-associated fatty liver disease.
Zheng K; Zhou W; Ji J; Xue Y; Liu Y; Li C; Zhang Z; Lu J; Shi X; Li Y
J Ethnopharmacol; 2023 Apr; 305():116081. PubMed ID: 36608777
[TBL] [Abstract][Full Text] [Related]
4. Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK/SREBP-1c/PPARα pathway.
Liu X; Hu M; Ye C; Liao L; Ding C; Sun L; Liang J; Chen Y
Chem Biol Interact; 2022 Dec; 368():110250. PubMed ID: 36347319
[TBL] [Abstract][Full Text] [Related]
5. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
6. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
Fang K; Wu F; Chen G; Dong H; Li J; Zhao Y; Xu L; Zou X; Lu F
BMC Complement Altern Med; 2019 Sep; 19(1):255. PubMed ID: 31519174
[TBL] [Abstract][Full Text] [Related]
7. Genistein has beneficial effects on hepatic steatosis in high fat-high sucrose diet-treated rats.
Liu H; Zhong H; Yin Y; Jiang Z
Biomed Pharmacother; 2017 Jul; 91():964-969. PubMed ID: 28514835
[TBL] [Abstract][Full Text] [Related]
8. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
9. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome.
Shen Q; Chen Y; Shi J; Pei C; Chen S; Huang S; Li W; Shi X; Liang J; Hou S
Eur J Pharmacol; 2023 Mar; 942():175504. PubMed ID: 36641101
[TBL] [Abstract][Full Text] [Related]
10. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
11. Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway.
Liu Y; Li Y; Wang J; Yang L; Yu X; Huang P; Song H; Zheng P
BMC Complement Med Ther; 2022 Aug; 22(1):213. PubMed ID: 35945571
[TBL] [Abstract][Full Text] [Related]
12. Digeda-4 decoction and its disassembled prescriptions improve dyslipidemia and apoptosis by regulating AMPK/SIRT1 pathway on tyloxapol-induced nonalcoholic fatty liver disease in mice.
Ji X; Ma Q; Wang X; Ming H; Bao G; Fu M; Wei C
J Ethnopharmacol; 2023 Dec; 317():116827. PubMed ID: 37348794
[TBL] [Abstract][Full Text] [Related]
13. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
14. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
[TBL] [Abstract][Full Text] [Related]
15. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanisms of Fucoxanthin in Alleviating Lipid Deposition in Metabolic Associated Fatty Liver Disease.
Yang S; Li J; Yan L; Wu Y; Zhang L; Li B; Tong H; Lin X
J Agric Food Chem; 2024 May; 72(18):10391-10405. PubMed ID: 38669300
[TBL] [Abstract][Full Text] [Related]
17. Tiaogan Jiejiu Tongluo Formula attenuated alcohol-induced chronic liver injury by regulating lipid metabolism in rats.
Fang C; Zhang J; Han J; Lei Y; Cao Z; Pan J; Pan Z; Zhang Z; Qu N; Luo H; Ma Y; Han D
J Ethnopharmacol; 2023 Dec; 317():116838. PubMed ID: 37355081
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha.
Ren L; Sun D; Zhou X; Yang Y; Huang X; Li Y; Wang C; Li Y
J Ethnopharmacol; 2019 Mar; 232():176-187. PubMed ID: 30590197
[TBL] [Abstract][Full Text] [Related]
19. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
[No Abstract] [Full Text] [Related]
20. Coniferaldehyde ameliorates the lipid and glucose metabolism in palmitic acid-induced HepG2 cells via the LKB1/AMPK signaling pathway.
Gai H; Zhou F; Zhang Y; Ai J; Zhan J; You Y; Huang W
J Food Sci; 2020 Nov; 85(11):4050-4060. PubMed ID: 33037652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
